Moving towards improved vaccines for Toxoplasma gondii

References

• Hill DE, Chirukandoth S, Dubey JP. Biology and epidemiology of Toxoplasma gondii in man and animals. Anim Health Res Rev. 2005;6(1):41–61.
   PubMedGoogle Scholar
• Nicolle C, Manceaux L. Sur une infection á corps de Leishman (ou organismes voisons) du gondi. CR Seances Acad. Sci. 1908;147:763–766.
   Google Scholar
• Dubey JP. History of the discovery of the life cycle of Toxoplasma gondii. Int J Parasitol. 2009;39(8):877–882.
   PubMed Web of Science ®Google Scholar
• Elmore SA, Jones JL, Conrad PA, et al. Toxoplasma gondii: epidemiology, feline clinical aspects, and prevention. Trends Parasitol. 2010;26(4):190–196.
   PubMed Web of Science ®Google Scholar
• Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: from animals to humans. Int J Parasitol. 2000;30(12–13):1217–1258.
   PubMed Web of Science ®Google Scholar
• Dubey JP. Infectivity and pathogenicity of Toxoplasma gondii oocysts for cats. J Parasitol. 1996;82(6):957–961.
   PubMed Web of Science ®Google Scholar
• Dubey JP, Lindsay DS, Speer CA. Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. Clin Microbiol Rev. 1998;11(2):267–299.
   PubMed Web of Science ®Google Scholar
• Cenci-Goga BT, Rossitto PV, Sechi P, et al. Toxoplasma in animals, food, and humans: an old parasite of new concern. Foodborne Pathog Dis. 2011;8(7):751–762.
   PubMed Web of Science ®Google Scholar
• Flegr J, Prandota J, Sovičková M. Toxoplasmosis – A global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries. PLoS One. 2014;9(3):e90203.
   PubMed Web of Science ®Google Scholar
• Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004;363(9425):1965–1976.
   PubMed Web of Science ®Google Scholar
• Robert-Gangneux F, Dardé M-L. Epidemiology of and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev. 2012;25(2):264–296.
   PubMed Web of Science ®Google Scholar
• Weiss LM, Dubey JP. Toxoplasmosis: a history of clinical observations. Int J Parasitol. 2009;39(8):895–901.
   PubMed Web of Science ®Google Scholar
• Bahia-Oliveira LMG, Jones JL, Azevedo-Silva J, et al. Highly endemic, waterborne toxoplasmosis in North Rio de Janeiro State, Brazil. Emerging Infectious Diseases. 2003;9(1):55–62.
   PubMed Web of Science ®Google Scholar
• de Barros JLVM, Barbosa IG, Salem H, et al. Is there any association between Toxoplasma gondii infection and bipolar disorder? A systematic review and meta-analysis. Journal of Affective Disorders. 2017;209:59–65.
   PubMed Web of Science ®Google Scholar
• Hill DE, Dubey JP. Toxoplasma gondii prevalence in farm animals in the United States. Int J Parasitol. 2013;43(2):107–113.
   PubMed Web of Science ®Google Scholar
• Garcia JL. Vaccination concepts against Toxoplasma gondii. Expert Rev Vaccines. 2009;8(2):215–225.
   PubMed Web of Science ®Google Scholar
• Zhang N-Z, Chen J, Wang M, et al. Vaccines against Toxoplasma gondii: new developments and perspectives. Expert Rev Vaccines. 2013;12(11):1287–1299.
   PubMed Web of Science ®Google Scholar
• Jongert E, Lemiere A, Van Ginderachter J, et al. Functional characterization of in vivo effector CD4(+) and CD8(+) T cell responses in acute Toxoplasmosis: an interplay of IFN-gamma and cytolytic T cells. Vaccine. 2010;28(13):2556–2564.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Orellana MA, Schreiber RD, et al. Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science. 1988;240(4851):516–518.
   PubMed Web of Science ®Google Scholar
• Buxton D, Thomson K, Maley S, et al. Vaccination of sheep with a live incomplete strain (S48) of Toxoplasma gondii and their immunity to challenge when pregnant. Vet Rec. 1991;129(5):89–93.
   PubMed Web of Science ®Google Scholar
• Buxton D, Innes EA. A commercial vaccine for ovine toxoplasmosis. Parasitology. 1995;110 Suppl(Suppl):SS11-6.
   Google Scholar
• Zhang N-Z, Wang M, Xu Y, et al. Recent advances in developing vaccines against Toxoplasma gondii: an update. Expert Rev Vaccines. 2015;14(12):1609–1621.
   PubMed Web of Science ®Google Scholar
• Joachim A. Vaccination against parasites – status quo and the way forward. Porcine Health Manag. 2016;2:30.
   PubMed Web of Science ®Google Scholar
• Kur J, Holec-Gąsior L, Hiszczyńska-Sawicka E. Current status of toxoplasmosis vaccine development. Expert Rev Vaccines. 2014;8(6):791–808.
   Google Scholar
• Fox BA, Bzik DJ. Nonreplicating, cyst-defective type II Toxoplasma gondii vaccine strains stimulate protective immunity against acute and chronic infection. Infect Immun. 2015;83(5):2148–2155.
   PubMed Web of Science ®Google Scholar
• Wang J, Elsheikha HM, Zhu WN, et al. Immunization with Toxoplasma gondii GRA17 deletion mutant induces partial protection and survival in challenged mice. Front Immunol. 2017;8:730.
   PubMed Web of Science ®Google Scholar
• Ching XT, Fong MY, Lau YL. Evaluation of immunoprotection conferred by the subunit vaccines of GRA2 and GRA5 against acute Toxoplasmosis in BALB/c mice. Front Microbiol. 2016;7:609.
   PubMed Web of Science ®Google Scholar
• Zulpo DL, Igarashi M, Sammi AS, et al. rROP2 from Toxoplasma gondii as a potential vaccine against oocyst shedding in domestic cats. Rev Bras Parasitol Vet. 2017;26(1):67–73.
   PubMed Web of Science ®Google Scholar
• Czarnewski P, Ecb A, Oliveira MC, et al. Recombinant TgHSP70 immunization protects against Toxoplasma gondii brain cyst formation by enhancing inducible nitric oxide expression. Front Cell Infect Microbiol. 2017;7:142.
   PubMed Web of Science ®Google Scholar
• Allahyari M, Mohabati R, Amiri S, et al. Synergistic effect of rSAG1 and rGRA2 antigens formulated in PLGA microspheres in eliciting immune protection against Toxoplasama gondii. Exp Parasitol. 2016;170:236–246.
   PubMed Web of Science ®Google Scholar
• Wang S, Wang Y, Sun X, et al. Protective immunity against acute toxoplasmosis in BALB/c mice induced by a DNA vaccine encoding Toxoplasma gondii 10 kDa excretory-secretory antigen (TgESA10). Vet Parasitol. 2015;214(1–2):40–48.
   PubMed Web of Science ®Google Scholar
• Liu Y, Cao A, Li Y, et al. Immunization with a DNA vaccine encoding Toxoplasma gondii Superoxide dismutase (TgSOD) induces partial immune protection against acute toxoplasmosis in BALB/c mice. BMC Infect Dis. 2017;17(1):403.
   PubMedGoogle Scholar
• Ahmadpour E, Sarvi S, Hashemi SSM, et al. Evaluation of the immune response in BALB/c mice induced by a novel DNA vaccine expressing GRA14 against Toxoplasma gondii. Parasite Immunol. 2017;39(4):e12419.
   Web of Science ®Google Scholar
• Chen J, Li ZY, Petersen E, et al. DNA vaccination with genes encoding Toxoplasma gondii antigens ROP5 and GRA15 induces protective immunity against toxoplasmosis in Kunming mice. Expert Rev Vaccines. 2015;14(4):617–624.
   PubMed Web of Science ®Google Scholar
• Gong P, Cao L, Guo Y, et al. Toxoplasma gondii: protective immunity induced by a DNA vaccine expressing GRA1 and MIC3 against toxoplasmosis in BALB/c mice. Exp Parasitol. 2016;166:131–136.
   PubMed Web of Science ®Google Scholar
• Zhu W, Wang J, Chen K, et al. Evaluation of protective immunity induced by DNA vaccination with genes encoding Toxoplasma gondii GRA17 and GRA23 against acute toxoplasmosis in mice. Exp Parasitol. 2017;179:20–27.
   PubMed Web of Science ®Google Scholar
• Zhang TE, Yin LT, Li RH, et al. Protective immunity induced by peptides of AMA1, RON2 and RON4 containing T- and B cell epitopes via an intranasal route against toxoplasmosis in mice. Parasit Vectors. 2015;8:15.
   PubMed Web of Science ®Google Scholar
• Cao A, Liu Y, Wang J, et al. Toxoplasma gondii: vaccination with a DNA vaccine encoding T- and B cell epitopes of SAG1, GRA2, GRA7 and ROP16 elicits protection against acute toxoplasmosis in mice. Vaccine. 2015;33(48):6757–6762.
   PubMed Web of Science ®Google Scholar
• Gotze S, Reinhardt A, Geissner A, et al. Investigation of the protective properties of glycosylphosphatidylinositol-based vaccine candidates in a Toxoplasma gondii mouse challenge model. Glycobiology. 2015;25(9):984–991.
   PubMed Web of Science ®Google Scholar
• Chuang SC, Chung YC, Yang CD. Protective immunity against toxoplasmosis in mice induced by single-dose immunization with rSAG1/2 protein released from poly (lactide-co-glycolide) microparticles. Parasite. 2017;24:5.
   PubMedGoogle Scholar
• Liu Q, Singla LD, Zhou H. Vaccines against Toxoplasma gondii: status, challenges and future directions. Hum Vaccin Immunother. 2012;8(9):1305–1308.
   PubMed Web of Science ®Google Scholar
• Fereig RM, Nishikawa Y. Towards a preventive strategy for toxoplasmosis: current trends, challenges, and future perspectives for vaccine development. Methods Mol Biol. 2016;1404:153–164.
   PubMedGoogle Scholar
• Wasmuth J, Daub J, Peregrin-Alvarez JM, et al. The origins of apicomplexan sequence innovation. Genome Res. 2009;19(7):1202–1213.
   PubMed Web of Science ®Google Scholar
• Wolff JA, Budker V. The mechanism of naked DNA uptake and expression. Adv Genet. 2005;54:3–20.
   PubMed Web of Science ®Google Scholar
• Carvalho JA, Rodgers J, Atouguia J, et al. DNA vaccines: a rational design against parasitic diseases. Expert Rev Vaccines. 2010;9(2):175–191.
   PubMed Web of Science ®Google Scholar
• Grzybowski MM, Gatkowska JM, Dziadek B, et al. Human toxoplasmosis: a comparative evaluation of the diagnostic potential of recombinant Toxoplasma gondii ROP5 and ROP18 antigens. J Med Microbiol. 2015;64(10):1201–1207.
   PubMedGoogle Scholar
• Rahimi MT, Sarvi S, Sharif M, et al. Immunological evaluation of a DNA cocktail vaccine with co-delivery of calcium phosphate nanoparticles (CaPNs) against the Toxoplasma gondii RH strain in BALB/c mice. Parasitol Res. 2017;116(2):609–616.
   PubMed Web of Science ®Google Scholar
• Suhrbier A. Multi-epitope DNA vaccines. Immunol Cell Biol. 1997;75(4):402–408.
   PubMed Web of Science ®Google Scholar
• Skwarczynski M, Toth I. Peptide-based synthetic vaccines. Chem Sci. 2016;7(2):842–854.
   PubMed Web of Science ®Google Scholar
• Carrière J, Barnich N, Nguyen HT. Exosomes: from functions in host-pathogen interactions and immunity to diagnostic and therapeutic opportunities. Rev Physiol Biochem Pharmacol. 2016;172:39–75.
   PubMed Web of Science ®Google Scholar
• Devhare PB, Ray RB. A novel role of exosomes in the vaccination approach. Ann Transl Med. 2017;5(1):23.
   PubMed Web of Science ®Google Scholar
• Beauvillain C, Juste MO, Dion S. Exosomes are an effective vaccine against congenital toxoplasmosis in mice. Vaccine. 2009;27(11):1750–1757.
   PubMed Web of Science ®Google Scholar
• Rodrigues JA, Acosta-Serrano A, Aebi M, et al. Parasite Glycobiology: a bittersweet symphony. Plos Pathog. 2015;11(11):e1005169.
   PubMed Web of Science ®Google Scholar
• Astronomo RD, Burton DR. Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov. 2010;9(4):308–324.
   PubMed Web of Science ®Google Scholar
• Jaurigue JA, Seeberger PH. Parasite carbohydrate vaccines. Front Cell Infect Microbiol. 2017;7:248.
   PubMed Web of Science ®Google Scholar
• Chahal JS, Khan OF, Cooper CL, et al. Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proc Natl Acad Sci USA. 2016;113(29):E4133–4142.
   PubMed Web of Science ®Google Scholar
• Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med. 2013;19(12):1597–1608.
   PubMed Web of Science ®Google Scholar
• Bonam SR, Partidos CD, Halmuthur SKM, et al. An overview of novel adjuvants designed for improving vaccine efficacy. Trends Pharmacol Sci. 2017;38(9):771–793.
   PubMed Web of Science ®Google Scholar
• Zhuo X, Sun H, Wang S, et al. Ginseng Stem-and-Leaf Saponin (GSLS)-enhanced protective immune responses induced by Toxoplasma gondii Heat Shocked Protein 70 (HSP70) against toxoplasmosis in mice. J Parasitol. 2017;103(1):111–117.
   PubMed Web of Science ®Google Scholar
• Hedhli D, Moiré N, Akbar H, et al. The antigen-specific response to Toxoplasma gondii profilin, a TLR11/12 ligand, depends on its intrinsic adjuvant properties. Med Microbiol Immunol. 2016;205(4):345–352.
   PubMed Web of Science ®Google Scholar
• Klippstein R, Pozo D. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Nanomedicine. 2010;6(4):523–529.
   PubMed Web of Science ®Google Scholar
• Dimier-Poisson I, Carpentier R, N’Guyen TT, et al. Porous nanoparticles as delivery system of complex antigens for an effective vaccine against acute and chronic Toxoplasma gondii infection. Biomaterials. 2015;50:164–175.
   PubMed Web of Science ®Google Scholar
• Chuang SC, Ko JC, Chen CP, et al. Induction of long-lasting protective immunity against Toxoplasma gondii in BALB/c mice by recombinant surface antigen 1 protein encapsulated in poly (lactide-co-glycolide) microparticles. Parasit Vectors. 2013;6:34.
   PubMed Web of Science ®Google Scholar
• Su C, Khan A, Zhou P, et al. Globally diverse Toxoplasma gondii isolates comprise six major clades originating from a small number of distinct ancestral lineages. Proc Natl Acad Sci USA. 2012;109(15):5844–5849.
   PubMed Web of Science ®Google Scholar
• Mestas J, Hughes CC, Mice O. Not men: differences between mouse and human immunology. J Immunol. 2004;172(5):2731–2738.
   PubMed Web of Science ®Google Scholar
• Innes EA. Toxoplasmosis: comparative species susceptibility and host immune response. Comp Immunol Microbiol Infect Dis. 1997;20(2):131–138.
   PubMed Web of Science ®Google Scholar